Retatrutide is currently the most potent metabolic peptide in clinical research. It simultaneously activates three receptors — GLP-1, GIP, and glucagon — making it the only triple agonist in the pipeline. The additional glucagon receptor activity is what sets it apart: it directly increases energy expenditure, not just appetite suppression.

Phase 2 clinical data from Eli Lilly showed average weight reductions of approximately 24% over 48 weeks at the highest dose — the largest reduction ever recorded for a pharmacological compound in a Phase 2 trial at the time of publication. Phase 3 trials are currently ongoing.

For researchers interested in the cutting edge of GLP-1 biology, retatrutide represents the most advanced triple-receptor compound currently available outside of approved pharmaceutical channels.

Tirzepatide is the current gold standard among approved metabolic peptides. It targets two receptors — GLP-1 and GIP — and is approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. The SURMOUNT Phase 3 programme showed average weight reductions of 20-22% over 72 weeks.

As an approved compound, tirzepatide has the most comprehensive clinical dataset of any next-generation metabolic peptide. Researchers studying dual incretin biology or comparing mechanisms with newer triple agonists use tirzepatide as the established benchmark.

Tesamorelin takes a different approach to fat loss compared to GLP-1 compounds. Rather than targeting appetite and glucose metabolism, it stimulates growth hormone release through the pituitary gland, which in turn drives visceral fat reduction. It is FDA-approved as Egrifta for HIV-associated lipodystrophy — the only growth hormone peptide with an approved clinical indication.

Research has consistently shown tesamorelin’s ability to reduce visceral adipose tissue specifically. Studies show significant reductions in trunk fat with relatively modest effects on appetite or other metabolic parameters. This makes it particularly interesting for researchers focused on abdominal fat reduction rather than total body weight.

MOTS-C takes a completely different approach. Rather than acting on appetite or growth hormone, this mitochondrial-derived peptide activates AMPK — one of the master regulators of cellular energy metabolism. Research has positioned MOTS-C as a potential exercise mimetic, with animal studies showing metabolic changes similar to those produced by physical training.

While the weight loss data for MOTS-C is less developed than the GLP-1 class, its unique mechanism makes it interesting for researchers studying metabolic flexibility, insulin sensitivity, and mitochondrial function alongside fat loss. MOTS-C levels also decline with age, making it relevant to both metabolic and longevity research.